Ibnsina Pharma Statistics

Total Valuation

Ibnsina Pharma has a market cap or net worth of EGP 8.94 billion. The enterprise value is 28.30 billion.

Market Cap	8.94B
Enterprise Value	28.30B

Important Dates

The next estimated earnings date is Thursday, May 22, 2025.

Earnings Date	May 22, 2025
Ex-Dividend Date	n/a

Share Statistics

Ibnsina Pharma has 1.01 billion shares outstanding.

Current Share Class	n/a
Shares Outstanding	1.01B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	26.01%
Owned by Institutions (%)	23.67%
Float	652.98M

Valuation Ratios

The trailing PE ratio is 17.96 and the forward PE ratio is 10.51.

PE Ratio	17.96
Forward PE	10.51
PS Ratio	0.16
PB Ratio	4.40
P/TBV Ratio	4.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.32, with an EV/FCF ratio of -23.89.

EV / Earnings	56.85
EV / Sales	0.51
EV / EBITDA	11.32
EV / EBIT	12.53
EV / FCF	-23.89

Financial Position

The company has a current ratio of 1.00, with a Debt / Equity ratio of 9.94.

Current Ratio	1.00
Quick Ratio	0.67
Debt / Equity	9.94
Debt / EBITDA	8.08
Debt / FCF	-17.05
Interest Coverage	1.34

Financial Efficiency

Return on equity (ROE) is 35.32% and return on invested capital (ROIC) is 7.67%.

Return on Equity (ROE)	35.32%
Return on Assets (ROA)	5.98%
Return on Invested Capital (ROIC)	7.67%
Return on Capital Employed (ROCE)	70.24%
Revenue Per Employee	10.15M
Profits Per Employee	90,508
Employee Count	5,500
Asset Turnover	2.37
Inventory Turnover	10.53

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +220.22% in the last 52 weeks. The beta is 0.41, so Ibnsina Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+220.22%
50-Day Moving Average	7.05
200-Day Moving Average	5.21
Relative Strength Index (RSI)	79.55
Average Volume (20 Days)	6,730,734

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Ibnsina Pharma had revenue of EGP 55.84 billion and earned 497.80 million in profits. Earnings per share was 0.49.

Revenue	55.84B
Gross Profit	4.40B
Operating Income	2.26B
Pretax Income	703.28M
Net Income	497.80M
EBITDA	2.39B
EBIT	2.26B
Earnings Per Share (EPS)	0.49

Full Income Statement

Balance Sheet

The company has 835.86 million in cash and 20.19 billion in debt, giving a net cash position of -19.36 billion or -19.21 per share.

Cash & Cash Equivalents	835.86M
Total Debt	20.19B
Net Cash	-19.36B
Net Cash Per Share	-19.21
Equity (Book Value)	2.03B
Book Value Per Share	2.02
Working Capital	47.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -926.58 million and capital expenditures -258.07 million, giving a free cash flow of -1.18 billion.

Operating Cash Flow	-926.58M
Capital Expenditures	-258.07M
Free Cash Flow	-1.18B
FCF Per Share	-1.18

Full Cash Flow Statement

Margins

Gross margin is 7.87%, with operating and profit margins of 4.04% and 1.10%.

Gross Margin	7.87%
Operating Margin	4.04%
Pretax Margin	1.26%
Profit Margin	1.10%
EBITDA Margin	4.28%
EBIT Margin	4.04%
FCF Margin	n/a

Dividends & Yields

Ibnsina Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	4.17%
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	5.57%
FCF Yield	-13.25%

Dividend Details

Stock Splits

The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.

Last Split Date	Jun 1, 2022
Split Type	Forward
Split Ratio	1.16666

Scores

Ibnsina Pharma has an Altman Z-Score of 2.38. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.38
Piotroski F-Score	n/a